Promising Potential of Oncolytics Biotech’s Pelareorep in KRAS-Mutant MSS Colorectal Cancer Drives Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating for Oncolytics Biotech, citing the potential of pelareorep in KRAS-mutant MSS colorectal cancer. The stock is expected to create significant value, with a price target of $10. Lake Street also maintained a Buy rating with a $7 target. Pelareorep shows promise in improving outcomes for MSS mCRC, a population resistant to existing therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments